Breast cancer: New data on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years

In the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.

from Breast Cancer News -- ScienceDaily https://ift.tt/2o9lhgs